DUBLIN – An evaluation of the first nine projects funded by the Innovative Medicines Initiative (IMI), the multibillion-euro public-private partnership involving the European Commission and the pharmaceutical industry, recommends that it broaden its focus from a "linear" approach to tackling pharma R&D bottlenecks to a "system-of-innovation" approach that can better identify pathways to socio-economic impact for individual projects.